Company intelligence / Profile preview

Sequel Pharma

California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Lead compound JTV-519 is in Phase 2 trials for atrial fibrillation; prior development in dermatological indications appears inactive. Five registered clinical trials are linked to company programs as of May 2025, but details on trial results require login for full results.

Therapeutic areas: DermatologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Japan TobaccoWashington University School of Medicine

Beyond the preview

Go deeper on Sequel Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequel Pharma.

Explore the full profile